Resistance to imatinib: mutations and beyond.

Abstract:

:Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the kinase domain of BCR-ABL as a major resistance mechanism have driven the development of second-generation TKIs. These agents are effective in a significant proportion of patients who fail to respond to imatinib. Clinical practice guidelines recommend using the BCR-ABL mutation genotype to aid selection of second-line treatment. Although kinase domain mutations are undoubtedly relevant to drug resistance, recent data suggest that additional resistance mechanisms must be operational in patients with and without kinase domain mutations. Clonal chromosomal evolution, BCR-ABL amplification, pharmacogenomic variations, or activation of signaling shortcuts have all been implicated in drug resistance, but their precise contributions to resistance remain to be determined. Additionally, lack of adherence to prescribed medication is likely to set the stage for resistance development. An area of intense research is primary resistance of leukemic stem cells (LSCs), which are thought to cause minimal residual disease to persist despite sustained treatment. The intent of this review is to shed light on the various aspects of TKI resistance in CML with respect to their biology and clinical implications.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

La Rosée P,Deininger MW

doi

10.1053/j.seminhematol.2010.06.005

subject

Has Abstract

pub_date

2010-10-01 00:00:00

pages

335-43

issue

4

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(10)00079-X

journal_volume

47

pub_type

杂志文章,评审
  • Improving the safety profile of warfarin.

    abstract::Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.34089

    authors: Chai SJ,Macik BG

    更新日期:2002-07-01 00:00:00

  • Towards molecular diagnosis and targeted therapy of lymphoid malignancies.

    abstract::Gene expression profiling of cancer began as a research tool but is rapidly moving towards clinical application. The diagnostic category of diffuse large B-cell lymphoma (DLBCL) can now be viewed as an amalgam of several different diseases that have distinct gene expression profiles, oncogenic mechanisms, and clinical...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(03)00194-x

    authors: Wiestner A,Staudt LM

    更新日期:2003-10-01 00:00:00

  • Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

    abstract::The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease. This review focuses on a series of new therapeutics ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2009.02.003

    authors: Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG

    更新日期:2009-04-01 00:00:00

  • Pentostatin for the treatment of indolent lymphoproliferative disorders.

    abstract::Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.12.005

    authors: Ho AD,Hensel M

    更新日期:2006-04-01 00:00:00

  • Leukocyte-endothelial cell interactions.

    abstract::Mechanisms that support migration of leukocytes have been studied extensively in vitro. The adhesion of neutrophils under conditions of flow at venous shear rates primarily involves members of the selectin family. E-selectin is upregulated by cytokine stimulation of endothelial cells (ECs); P-selectin is upregulated b...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith CW

    更新日期:1993-10-01 00:00:00

  • Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.

    abstract::A retrospective study was conducted to determine treatment patterns for idiopathic thrombocytopenia purpura (ITP) across the US and to determine the cost of its treatment with high-dose intravenous immunoglobulin (IVIg) and anti-D therapy. Information on the incidence, treatment patterns, hospital care, and costs for ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Simpson KN,Coughlin CM,Eron J,Bussel JB

    更新日期:1998-01-01 00:00:00

  • Shwachman-Diamond syndrome.

    abstract::Shwachman-Diamond syndrome (SDS) is an autosomal recessive marrow failure syndrome associated with exocrine pancreatic insufficiency and leukemia predisposition. Bone marrow failure typically manifests with neutropenia, but anemia, thrombocytopenia, or aplastic anemia may also develop. Additional organ systems, such a...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2006.04.006

    authors: Shimamura A

    更新日期:2006-07-01 00:00:00

  • Mismatched unrelated donor transplantation.

    abstract::There are now more than 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although a human leukocyte antigen (HLA)-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.07.003

    authors: Petersdorf EW

    更新日期:2016-10-01 00:00:00

  • Proteasome inhibition for antibody-mediated allograft rejection.

    abstract::Antibody-mediated rejection (AMR) is a major risk factor for graft loss following kidney transplantation. Traditional anti-humoral therapies provide suboptimal therapy and they do not deplete plasma cells, which are the source of antibody production. Proteasome inhibitors (PI) have been shown to deplete both transform...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2012.04.008

    authors: Sadaka B,Alloway RR,Shields AR,Schmidt NM,Woodle ES

    更新日期:2012-07-01 00:00:00

  • Copper deficiency in humans.

    abstract::Copper is an essential trace element that is required for a number of enzymes which are necessary for normal metabolic function. Metabolic balance studies have demonstrated that daily copper losses are approximately 1.3 mg/day. In order to remain in copper balance, the average adult male must consume a diet which cont...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams DM

    更新日期:1983-04-01 00:00:00

  • The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.

    abstract::Untreated anemia is common in cancer patients. Previous studies have demonstrated that both the existence of cancer and treatment with chemotherapy can suppress the normal endogenous erythropoietic response to anemia, making some cancer patients transfusion cadidates. In placebo-controlled phase III studies, administr...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Glaspy J

    更新日期:1997-07-01 00:00:00

  • Limitations of conventional treatment options for heparin-induced thrombocytopenia.

    abstract::Thrombosis is a common and potentially serious complication of immune-mediated heparin-induced thrombocytopenia (HIT). Discontinuation of heparin is a simple and important maneuver in patients with suspected HIT. Unfortunately, thrombosis often occurs even in those patients in whom heparin was discontinued because of ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Warkentin TE

    更新日期:1998-10-01 00:00:00

  • High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.

    abstract::The use of combination chemotherapy has been successful in treating advanced or widespread Hodgkin's disease (HD). For patients with relapsed disease, the long-term prognosis is much poorer, despite the good rate of reinduction into a second or further remission using conventional treatments. The majority of such pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Laurence AD,Goldstone AH

    更新日期:1999-07-01 00:00:00

  • Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation.

    abstract::Even though the overall outcome after allogeneic transplant has improved significantly in the last decades, late infectious diseases are still the most important causes of late morbidity and mortality. Here, impaired immune reconstitution and therapy of chronic graft-versus-host disease (GVHD) represent the major risk...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.10.009

    authors: Fuji S,Kapp M,Einsele H

    更新日期:2012-01-01 00:00:00

  • Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.

    abstract::Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML). With the exception of allogeneic stem cell transplantation, there is generally no curative treatment for these d...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.02.002

    authors: Fenaux P

    更新日期:2004-04-01 00:00:00

  • Flow cytometry in human leukocyte antigen testing.

    abstract::Stem cell transplantation is a recognized treatment for many hematologic malignancies. Human leukocyte antigen (HLA) testing is a key assessment in the evaluation of potential recipients and selection of the appropriate stem cell donor. Over the past several years, technological advances have moved HLA testing from a ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90052-6

    authors: Bray RA

    更新日期:2001-04-01 00:00:00

  • Thrombopoietin receptor agonists in primary immune thrombocytopenia.

    abstract::Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO recepto...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.005

    authors: Siegal D,Crowther M,Cuker A

    更新日期:2013-01-01 00:00:00

  • Mismatched unrelated alternative donors for hematological malignancies.

    abstract::For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.01.009

    authors: Sebastian Schäfer H,Finke J

    更新日期:2016-04-01 00:00:00

  • Management of cancer-related anemia: epoetin alfa and quality of life.

    abstract::Anemia is frequent and significantly adds to the morbidity of cancer patients, and has been associated with decreased quality of life (QOL). Three open-label community-based studies of epoetin alfa in cancer-related anemia (two using three-times-weekly dosing and one using once-weekly dosing) in more than 7,000 patien...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90062-3

    authors: Soignet S

    更新日期:2000-10-01 00:00:00

  • Molecular evaluation of acute myeloid leukemias.

    abstract::Traditionally, acute myeloid leukemia (AML) has been diagnosed and classified based on the morphologic and cytochemical criteria of the French-American-British (FAB) classification system. However, more recent studies have demonstrated that the cytogenetic and molecular genetic abnormalities consistently associated wi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Willman CL

    更新日期:1999-10-01 00:00:00

  • Improving CAR T-cells: The next generation.

    abstract::The introduction of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL) has dramatically altered the landscape of treatment options available to children and adults with ALL. With complete remission induction rates exceeding 70% in most trials and FDA approval of one CD19 CAR T-cell co...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2020.07.002

    authors: Marple AH,Bonifant CL,Shah NN

    更新日期:2020-07-01 00:00:00

  • Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.

    abstract::In early studies, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to reduce the depth and duration of granulocytopenia in the settings of cancer chemotherapy and autologous bone marrow transplantation. In patients with myelodysplastic syndrome or aplastic anemia. GM-CSF has p...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Gutterman J,Vadhan-Raj S,Logothetis C,Anaissle E,Estey E,Talpaz M,Kurzrock R

    更新日期:1990-07-01 00:00:00

  • Impact of social media for the hematologist/oncologist.

    abstract::In the era of modern communication, the physician and patient relationship has evolved to include an entirely new dimension-social media. This new dimension offers several opportunities for patient education, research and its dissemination, and professional development for health care providers; it can also serve as a...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.07.003

    authors: Abuhadra N,Majhail NS,Nazha A

    更新日期:2017-10-01 00:00:00

  • TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.

    abstract::TET2 is one of the most frequently mutated genes in myeloid neoplasms. TET2 loss-of-function perturbs myeloid differentiation and causes clonal expansion. Despite extensive knowledge regarding biochemical mechanisms underlying distorted myeloid differentiation, targeted therapies are lagging. Here we review known bioc...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2020.12.002

    authors: Guan Y,Hasipek M,Tiwari AD,Maciejewski JP,Jha BK

    更新日期:2021-01-01 00:00:00

  • Prognostic relevance of clinical risk factors in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) has only recently been recognized as a separate biologically defined lymphoma entity. Due to its low incidence, many reports on clinical prognostic factors are limited by small patient numbers. The MCL International Prognostic Index (MIPI) was developed using data of more than 400 patients t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.06.001

    authors: Hoster E

    更新日期:2011-07-01 00:00:00

  • Myelodysplastic syndromes.

    abstract::These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to ident...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Koeffler HP

    更新日期:1996-04-01 00:00:00

  • Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

    abstract::Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling is the treatment of choice in children and young adults with severe aplastic anemia (SAA). However, because only 30% of patients have a suitable donor, more aggressive nontransplant immunosuppressive regimens have been used, with re...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90029-5

    authors: Margolis DA,Casper JT

    更新日期:2000-01-01 00:00:00

  • Familial thrombophilia: a complex genetic disorder.

    abstract::Familial thrombosis has long been considered as an autosomal dominant trait, caused by a dominant gene defect with a reduced penetrance for the disease. Recently, this view has changed and today familial thrombophilia is considered as a complex genetic disorder caused by the segregation of two or more gene defects (kn...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Koeleman BP,Reitsma PH,Bertina RM

    更新日期:1997-07-01 00:00:00

  • The virome in hematology-Stem cell transplantation and beyond.

    abstract::The virome has been recently studied in hematology and mostly in the setting of allogeneic hematopoietic stem cell transplantation. However, in hematology (as in the setting of nonhematological disorders) the study of the microbiome (that indeed includes the virome) is a growing field. The overall field is moving beyo...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2020.05.001

    authors: Legoff J,Michonneau D,Socie G

    更新日期:2020-01-01 00:00:00

  • Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura.

    abstract::Idiopathic thrombocytopenic purpura (ITP) is an illness of primary acquired thrombocytopenia occurring in the absence of marrow failure. Splenectomy was first used as a treatment for ITP in 1913. However, with the realization that opsonin (critical for the optimal killing of invasive micro-organisms by white blood cel...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90114-8

    authors: Bell WR Jr

    更新日期:2000-01-01 00:00:00